Zobrazeno 1 - 7
of 7
pro vyhledávání: '"John P. Lawo"'
Autor:
Tomoo Fukuda, Keiko Yamagami, Kimito Kawahata, Yuzo Suzuki, Yoshihiro Sasaki, Takashi Miyagi, Iris Jacobs, John-Philip Lawo, Fiona Glassman, Hideto Akama, Michihiro Hide, Isao Ohsawa
Publikováno v:
Allergology International, Vol 72, Iss 3, Pp 451-457 (2023)
Background: Hereditary angioedema (HAE) is a rare and potentially life-threatening genetic disorder characterized by recurrent attacks of angioedema. HAE types I and II result from deficient or dysfunctional C1-esterase inhibitor (C1–INH). This Pha
Externí odkaz:
https://doaj.org/article/41fb99ae42094f549215fbbd33660195
Autor:
Michael A. Tortorici, Theresa Yuraszeck, David Cornblath, Vera Bril, Hans‐Peter Hartung, Gen Sobue, Richard A. Lewis, Ingemar S. J. Merkies, John‐Philip Lawo, Michaela Praus, Billie L. Durn, Orell Mielke, Xuewen Ma, Petra Jauslin, Marc Pfister, Ivo N. vanSchaik, the PATH study group
Publikováno v:
CPT: Pharmacometrics & Systems Pharmacology, Vol 10, Iss 8, Pp 839-850 (2021)
Abstract The two main objectives of this analysis were to (i) characterize the relationship between immunoglobulin (Ig) exposure and chronic inflammatory demyelinating polyneuropathy (CIDP) disease severity using data from 171 patients with CIDP who
Externí odkaz:
https://doaj.org/article/864b1de80a0d49abab9c2cf35b4c5ae2
Autor:
William R. Lumry, Bruce Zuraw, Marco Cicardi, Timothy Craig, John Anderson, Aleena Banerji, Jonathan A. Bernstein, Teresa Caballero, Henriette Farkas, Richard G. Gower, Paul K. Keith, Donald S. Levy, H. Henry Li, Markus Magerl, Michael Manning, Marc A. Riedl, John-Philip Lawo, Subhransu Prusty, Thomas Machnig, Hilary Longhurst, on behalf of the COMPACT Investigators
Publikováno v:
Orphanet Journal of Rare Diseases, Vol 16, Iss 1, Pp 1-14 (2021)
Abstract Background Long-term prophylaxis with subcutaneous C1-inhibitor (C1-INH[SC]; HAEGARDA, CSL Behring) in patients with hereditary angioedema (HAE) due to C1-INH deficiency (C1-INH-HAE) was evaluated in an open-label extension follow-up study t
Externí odkaz:
https://doaj.org/article/3d0ee6580c494bd3a3f9bff57e907f0f
Autor:
Jonathan A. Bernstein, Huamin Henry Li, Timothy J. Craig, Michael E. Manning, John-Philip Lawo, Thomas Machnig, Girishanthy Krishnarajah, Moshe Fridman
Publikováno v:
Allergy, Asthma & Clinical Immunology, Vol 15, Iss 1, Pp 1-9 (2019)
Abstract Introduction For prophylaxis of hereditary angioedema (HAE) attacks, replacement therapy with human C1-inhibitor (C1-INH) treatment is approved and available as intravenous [C1-INH(IV)] (Cinryze®) and subcutaneous [C1-INH(SC)] HAEGARDA® pr
Externí odkaz:
https://doaj.org/article/873c84b960bf4a1383c8018a2ffd5217
Autor:
William R. Lumry, Bruce Zuraw, Marco Cicardi, Timothy Craig, John Anderson, Aleena Banerji, Jonathan A. Bernstein, Teresa Caballero, Henriette Farkas, Richard G. Gower, Paul K. Keith, Donald S. Levy, H. Henry Li, Markus Magerl, Michael Manning, Marc A. Riedl, John-Philip Lawo, Subhransu Prusty, Thomas Machnig, Hilary Longhurst, the COMPACT Investigators
Publikováno v:
Orphanet Journal of Rare Diseases, Vol 16, Iss 1, Pp 1-2 (2021)
Externí odkaz:
https://doaj.org/article/d80ded04a23e4f01b4918bb890575a6e
Autor:
Alphonse Hubsch, Abdulgabar Salama, Stefano Fontana, Orell Mielke, Vesselina Goranova-Marinova, Sandra Wymann, Billie L. Durn, Martin O. Spycher, John P. Lawo, Amgad Shebl
Publikováno v:
Transfusion. 57:2629-2638
BACKGROUND Patients treated with intravenous immunoglobulins (IVIG) rarely experience symptomatic hemolysis. Although anti-A and anti-B isoagglutinins from the product are involved in most cases, the actual mechanisms triggering hemolysis are unclear
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f7e75242fe10184069364ce48c801e57
https://doi.org/10.1111/trf.14289
https://doi.org/10.1111/trf.14289
Autor:
Orell, Mielke, Stefano, Fontana, Vesselina, Goranova-Marinova, Amgad, Shebl, Martin O, Spycher, Sandra, Wymann, Billie L, Durn, John P, Lawo, Alphonse, Hubsch, Abdulgabar, Salama
Publikováno v:
Transfusion. 57(11)
Patients treated with intravenous immunoglobulins (IVIG) rarely experience symptomatic hemolysis. Although anti-A and anti-B isoagglutinins from the product are involved in most cases, the actual mechanisms triggering hemolysis are unclear.A prospect
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::6d3d0d2c921d0b8725d9ebfcb4890753
https://pubmed.ncbi.nlm.nih.gov/28840942
https://pubmed.ncbi.nlm.nih.gov/28840942